Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Sanofi-Aventis S.A. ADR (NQ: SNY )

48.00 +0.26 (+0.54%)
Streaming Delayed Price Updated: 4:00 PM EDT, Mar 20, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 2,231,960
Open 47.96
Bid (Size) 48.24 (7)
Ask (Size) 48.50 (3)
Prev. Close 47.74
Today's Range 47.63 - 48.24
52wk Range 36.91 - 58.10
Shares Outstanding 1,250,690,553
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year

Top News

More News
Credit Suisse's $17B Of AT1 Debt Written Down To Zero, Richard Branson's Virgin Orbit Plans Insolvency, Court Freezes Volkswagen's Russian Assets: Today's Top Stories
Reuters 
Via Benzinga
Large Vaccine Players Including GSK, Moderna Prepare For Bird Flu Vaccine 'Just In Case'
 
Via Benzinga

Performance

YTD
-2.04%
-2.04%
1 Month
+0.84%
+0.84%
3 Month
+2.17%
+2.17%
6 Month
+18.26%
+18.26%
1 Year
-5.79%
-5.79%

More News

Read More
Dupixent® (dupilumab) Late-Breaking Data at AAD Show Significant Improvements in Signs and Symptoms of Moderate-to-severe Atopic Hand and Foot Dermatitis
From Regeneron Pharmaceuticals, Inc.
Via Globe NewsWire
Stock Market Diverges Amid Bank Woes, Growth Gains; First Republic, Credit Suisse, Meta In Focus: Weekly Review
Via Investor's Business Daily
Acer Therapeutics' Product Acquired From Sanofi Fails In Menopause Study
Via Benzinga
SVB Financial Officially Files For Bankruptcy, Yellen, Powell & Dimon Behind First Republic Bank's $30B Lifeline, Playboy's $5M Loss On Ethereum: Today's Top Stories
Via Benzinga
Three Is Company - Sanofi Follows Lilly, Novo Nordisk, Slashes Insulin Product Price By 78%
Via Benzinga
Why Provention Bio Stock Skyrocketed 256% This Week
Via The Motley Fool
What's Going On With Sanofi Stock After Hours?
Via Benzinga
2 Top Biotech Stocks to Buy Right Now
Via The Motley Fool
Provention Bio's $2.9B Acquisition - A Strategic Fit For Sanofi
Via Benzinga
How Is The Market Feeling About Sanofi?
Via Benzinga
Monday Merger Mania Just Made These 2 Biotech Stocks Big Winners
Via The Motley Fool
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Qualtrics (Nasdaq - XM), Seagen Inc. (Nasdaq - SGEN), Provention Bio Inc. (Nasdaq - PRVB), Kimball International, Inc. (Nasdaq – KBAL)
From Brodsky & Smith LLC
Via Globe NewsWire
Sanofi (NASDAQ: SNY) Set to Acquire Provention Bio (NASDAQ: PRVB) for $2.9 Billion
Via Spotlight Growth
Pfizer Officially Nabs Seagen For $43 Billion; Provention Soars On Sanofi Deal
Via Investor's Business Daily
Why Provention Bio Stock Is Rocketing Past 52-Week Highs Today
Via Benzinga
Why Is Provention Bio (PRVB) Stock Up 263% Today?
Via InvestorPlace
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday
Via InvestorPlace
Nasdaq Futures Climb Solidly After Past Week's Rout: Analyst Flags Key S&P 500 Support To Stay Above October Lows
Via Benzinga
Sanofi, AstraZeneca Tee Up A Rival To Pfizer In The Multibillion-Dollar RSV Race
Via Investor's Business Daily
7 Blue-Chip Stocks to Buy for Quality-Focused Investors
Via InvestorPlace
Sanofi Could Be on a Roll With a Strong Performance and Its Latest FDA Approval
Via The Motley Fool
FDA Approves Regeneron-Sanofi's Sarilumab As First Biologic For Stiffness, Pain In Muscles
Via Benzinga
Eli Lilly Slashes Insulin Prices By 70%, Will Other Insulin Makers Follow Suit?
Via Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.